Spread of OnabotulinumtoxinA After Bladder Injection. Experimental Study Using the Distribution of Cleaved SNAP-25 as the Marker of the Toxin Action

Coelho, Ana; Cruz, Francisco; Cruz, Carlos Oliveira; Avelino, António

doi:10.1016/j.eururo.2012.01.046

Cited by 74 publications

(81 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BoNT acts by cleaving the synaptosome-associated protein of 25 kDa (SNAP-25) in the tissue [12]. A recent study characterized the diffusion pattern of BoNT in the guinea pig bladders using the expression of SNAP-25 following different injection volumes [12].…”

Section: Discussionmentioning

confidence: 99%

Delayed contrast-enhanced MRI to localize Botox after cystoscopic intravesical injection

et al. 2015

View full text Add to dashboard Cite

Diffusion of BoNT after intravesical injection is very common once bladder wall is breeched. Precise injection localization into muscle layer may not be as relevant to outcome as previously assumed. The assumption in our study that localization and diffusion of contrast also represents the localization of BoNT is open to critique as BoNT diffusion is potentially slower (Mehnert et al. in World J Urol 27(3):397-403, 2009). The absence of systemic symptoms after the injection in our series supports guidelines concerning the safety of procedure.

show abstract

Section: Discussionmentioning

confidence: 99%

Delayed contrast-enhanced MRI to localize Botox after cystoscopic intravesical injection

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The reasons might be a short retention of BTX-A in the colon, insufficient absorption of BTX-A, as well as an inability of BTX-A to enter the nerves from the lumen of the colon. The later seems likely since it was demonstrated that after instillation into the lumen of the bladder in guinea pigs, BTX-A does not enter the nerve fibers (Coelho et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

Antinociceptive effect of botulinum toxin type A on experimental abdominal pain

Drinovac

Bach-Rojecky

Babić

et al. 2014

European Journal of Pharmacology

View full text Add to dashboard Cite

“…16 In an animal study, cleaved SNAP25, the end product of the enzymatic activity of the BoNTA light chain, was detected predominantly in parasympathetic nerves. 17 For this reason, cleaved SNAP25 is considered an ideal marker of sites of BoNTA action and, there fore, an important target in future research. 17,18 Despite this apparent accumulation of BoNTA in parasympa thetic nerves, in 2014, the presence of binding protein SV2 as well as the target protein SNAP25 was demon strated within the bladder mucosa using immunohisto chemical staining and western blotting methods.…”

Section: Mechanisms Of Actionmentioning

confidence: 99%

“…17 For this reason, cleaved SNAP25 is considered an ideal marker of sites of BoNTA action and, there fore, an important target in future research. 17,18 Despite this apparent accumulation of BoNTA in parasympa thetic nerves, in 2014, the presence of binding protein SV2 as well as the target protein SNAP25 was demon strated within the bladder mucosa using immunohisto chemical staining and western blotting methods. 19,20 This finding indicates that the effects of BoNTA in the urinary bladder are more complex than previously thought, and intravesical delivery of BoNTA into the urothelium by might be both possible and clinically relevant.…”

Section: Mechanisms Of Actionmentioning

confidence: 99%

Current and potential urological applications of botulinum toxin A

Jiang

Liao

2015

Nat Rev Urol

View full text Add to dashboard Cite

Botulinum toxin subtype A (BoNT-A) is a potent neurotoxin that can selectively modulate neurotransmitter release from nerve endings, resulting in muscular paralysis. BoNT-A might also act on sensory nerves, and have an anti-inflammatory effect. In the first urological use of BoNT-A, injection into the urethral sphincters of patients with detrusor-sphincter dyssynergia resulted in a reduction of urethral resistance and improved voiding efficiency. Subsequently, intravesical BoNT-A injections have received regulatory approval for treatment of neurogenic detrusor overactivity owing to spinal cord lesions or multiple sclerosis, and idiopathic overactive bladder in adults. BoNT-A has also been widely used to treat patients with the off-label indications of neurogenic or non-neurogenic voiding dysfunction and male lower urinary tract symptoms owing to BPH and bladder-neck dysfunction. Other indications for which urologists have applied BoNT-A injections include interstitial cystitis/bladder pain syndrome, bladder oversensitivity and chronic pelvic pain syndrome. BoNT-A is currently delivered as an intravesical injection; however, use of liposome encapsulated formulations is also beginning to show some therapeutic potential.

show abstract

Spread of OnabotulinumtoxinA After Bladder Injection. Experimental Study Using the Distribution of Cleaved SNAP-25 as the Marker of the Toxin Action

Cited by 74 publications

References 21 publications

Delayed contrast-enhanced MRI to localize Botox after cystoscopic intravesical injection

Delayed contrast-enhanced MRI to localize Botox after cystoscopic intravesical injection

Antinociceptive effect of botulinum toxin type A on experimental abdominal pain

Current and potential urological applications of botulinum toxin A

Contact Info

Product

Resources

About